• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

    2/13/24 4:58:56 PM ET
    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIP alert in real time by email
    SC 13G 1 tv0292-anipharmaceuticalsinc.htm SCHEDULE 13G anipharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  ANI Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  00182C103

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  00182C103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    23,630

    7.  SOLE DISPOSITIVE POWER

    1,250,867

    8.  SHARED DISPOSITIVE POWER

    38,105

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,288,972

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.31%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ANI Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    210 Main Street West
    Baudette, MN 56623

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    00182C103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ANIP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANIP

    DatePrice TargetRatingAnalyst
    3/14/2025$80.00Buy
    Jefferies
    3/12/2025$85.00Overweight
    Analyst
    12/11/2024$80.00Outperform
    Leerink Partners
    10/11/2024$68.00Overweight
    Piper Sandler
    3/15/2024$80.00Overweight
    CapitalOne
    8/22/2023$60.00 → $73.00Buy
    H.C. Wainwright
    3/1/2023$55.00Buy
    Guggenheim
    9/7/2022$50.00Buy
    H.C. Wainwright
    More analyst ratings

    $ANIP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model

      Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. "In a preclinical model of autoimmune uveitis, Cortrophin Gel reduced levels of inflammatory molecules without stimulating an adverse immune response," said Mary Pao, MD, PhD, Chief Medical Officer of Rare Disease at ANI. "The results further support our understandin

      5/5/25 7:00:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section           A re

      4/9/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Financials

    Live finance-specific insights

    See more
    • ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%Total Rare Disease quarterly net revenues of $69.0 million, which includes: Purified Cortrophin® Gel net revenues of $52.9 million, an increase of 43.1% year-over-year, andILUVIEN® and YUTIQ® net revenues of $16.1 million Record Generics net revenues of $98.7 million, an increase of 40.5% year-over-yearDelivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-yearDiluted GAAP income per share of $0.69 and record adjusted non-GAAP diluted earnings per share of $1.70Increased 2025 guidance with expected net revenues of $768.0 million to $793.0 million

      5/9/25 6:50:08 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET

      PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 Time8:00 a.m. ET Toll free (U.S.)800-225-9448 Conference ID4921902 Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section           A re

      4/9/25 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance

      Generated record quarterly net revenues of $190.6 million, representing year-over-year growth of 44.8%Total Rare Disease quarterly net revenue of $87.0 million, which includes: Record quarterly net revenue for Purified Cortrophin® Gel of $59.4 million, an increase of 42.3% year-over-year, andILUVIEN® and YUTIQ® net revenues of $27.6 million in the first full quarter of ownership following the acquisition of Alimera Sciences Delivered record quarterly adjusted non-GAAP EBITDA of $50.0 million, an increase of 65.7% year-over-yearDiluted GAAP loss per share of $(0.55) and adjusted non-GAAP diluted earnings per share of $1.63Increased 2025 guidance with expected net revenu

      2/28/25 6:50:16 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Leadership Updates

    Live Leadership Updates

    See more
    • Alcami Announces CEO Transition

      Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

      1/13/25 11:12:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

      -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

      8/23/23 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

      ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

      9/12/22 6:50:00 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on ANI Pharma with a new price target

      Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00

      3/14/25 7:26:09 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on ANI Pharma with a new price target

      Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00

      3/12/25 7:20:36 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on ANI Pharma with a new price target

      Leerink Partners initiated coverage of ANI Pharma with a rating of Outperform and set a new price target of $80.00

      12/11/24 7:21:57 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $27,584 worth of shares (400 units at $68.96), decreasing direct ownership by 0.50% to 80,145 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      4/14/25 4:17:11 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Lalwani Nikhil covered exercise/tax liability with 17,455 shares, decreasing direct ownership by 4% to 468,179 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      3/25/25 4:47:48 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP & CFO Carey Stephen P. covered exercise/tax liability with 6,210 shares, decreasing direct ownership by 3% to 180,863 units (SEC Form 4)

      4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)

      3/25/25 4:44:49 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    SEC Filings

    See more
    • SEC Form 10-Q filed by ANI Pharmaceuticals Inc.

      10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/9/25 6:57:59 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/9/25 6:55:20 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ANI Pharmaceuticals Inc.

      DEFA14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)

      5/8/25 9:15:39 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

      Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

      3/8/21 5:11:24 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OXYCODONE AND ASPIRIN

      Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

      3/8/21 5:11:06 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for EZETIMIBE AND SIMVASTATIN

      Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

      2/25/21 5:09:42 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ANI Pharmaceuticals Inc.

      SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      11/13/24 4:30:24 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ANI Pharmaceuticals Inc. (Amendment)

      SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      3/14/24 7:30:38 AM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ANI Pharmaceuticals Inc.

      SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)

      2/13/24 4:58:56 PM ET
      $ANIP
      Biotechnology: Pharmaceutical Preparations
      Health Care